Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Relapsed refractory multiple myeloma: a comprehensive overview
Abdul Hamid Bazarbachi, Rama Al Hamed, Florent Malard, et al.
Leukemia (2019) Vol. 33, Iss. 10, pp. 2343-2357
Closed Access | Times Cited: 133

Showing 1-25 of 133 citing articles:

BCMA-targeted immunotherapy for multiple myeloma
Bo Yu, Tianbo Jiang, Delong Liu
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 160
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
Anita D’Souza, Nina Shah, Cesar Rodriguez, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 31, pp. 3576-3586
Open Access | Times Cited: 84
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
Saad Z. Usmani, Hang Quach, María‐Victoria Mateos, et al.
The Lancet Oncology (2021) Vol. 23, Iss. 1, pp. 65-76
Closed Access | Times Cited: 69
Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications
Sherry Bhalla, David T. Melnekoff, Adolfo Aleman, et al.
Science Advances (2021) Vol. 7, Iss. 47
Open Access | Times Cited: 66
The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma
Josh N. Vo, Yi‐Mi Wu, Jeanmarie Mishler, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 56
Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient Administration
Maurice Alexander, Kathryn A. Culos, Julianna Roddy, et al.
Transplantation and Cellular Therapy (2021) Vol. 27, Iss. 7, pp. 558-570
Open Access | Times Cited: 54
Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update
Abdul Hamid Bazarbachi, Rama Al Hamed, Florent Malard, et al.
Blood Cancer Journal (2022) Vol. 12, Iss. 3
Open Access | Times Cited: 36
Pathogenesis and treatment of multiple myeloma
Peipei Yang, Ying Qu, Mengyao Wang, et al.
MedComm (2022) Vol. 3, Iss. 2
Open Access | Times Cited: 28
Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects
Grace Lassiter, Cole Bergeron, Ryan Guedry, et al.
Current Oncology (2021) Vol. 28, Iss. 1, pp. 640-660
Open Access | Times Cited: 38
Isatuximab: A Review of Its Use in Multiple Myeloma
James E. Frampton
Targeted Oncology (2021) Vol. 16, Iss. 5, pp. 675-686
Open Access | Times Cited: 35
Advances in Management for Older Adults With Hematologic Malignancies
Ashley Rosko, Raúl Córdoba, Gregory A. Abel, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 19, pp. 2102-2114
Open Access | Times Cited: 33
Cost-Effectiveness Analysis of CAR T-Cell Therapies vs Antibody Drug Conjugates for Patients with Advanced Multiple Myeloma
Kandice A. Kapinos, Ellen Hu, Jigar Trivedi, et al.
Cancer Control (2023) Vol. 30
Open Access | Times Cited: 15
The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial
Ehsan Malek, Priyanka S. Rana, Muthulekha Swamydas, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 5
Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma
Hyunsoo Cho, Kyung Hwan Kim, Hoyoung Lee, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 10, pp. 2947-2958
Open Access | Times Cited: 29
Gene Expression Profiling Identifies CAV1, CD44, and TFRC as Potential Diagnostic Markers and Therapeutic Targets for Multiple Myeloma
Awais Ali, Syed Luqman Ali, Waseef Ullah, et al.
Cell Biochemistry and Biophysics (2025)
Closed Access
NEDD4L binds the proteasome and promotes autophagy and bortezomib sensitivity in multiple myeloma
Xi Huang, Wen Cao, Shunnan Yao, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 3
Open Access | Times Cited: 16
Single-cell technologies in multiple myeloma: new insights into disease pathogenesis and translational implications
Mengping Chen, Jinxing Jiang, Jian Hou
Biomarker Research (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 10
The mitochondrial pyruvate carrier complex potentiates the efficacy of proteasome inhibitors in multiple myeloma
Steven Findlay, Remya Nair, Ronald A. Merrill, et al.
Blood Advances (2023) Vol. 7, Iss. 14, pp. 3485-3500
Open Access | Times Cited: 9
Cost effectiveness analysis of CAR-T cell therapy for patients with relapsed/refractory multiple myeloma in China
Weijia Wu, Shuyi Ding, Mingming Zhang, et al.
Journal of Medical Economics (2023) Vol. 26, Iss. 1, pp. 701-709
Open Access | Times Cited: 9
Multiple myeloma with high expression of SLC7A11 is sensitive to erastin-induced ferroptosis
Weimin Zhang, Qi Li, Yuchen Zhang, et al.
APOPTOSIS (2023) Vol. 29, Iss. 3-4, pp. 412-423
Closed Access | Times Cited: 9
Bortezomib elevates intracellular free Fe2+ by enhancing NCOA4-mediated ferritinophagy and synergizes with RSL-3 to inhibit multiple myeloma cells
Yanyan Zhang, Fen He, Wei Hu, et al.
Annals of Hematology (2024) Vol. 103, Iss. 9, pp. 3627-3637
Closed Access | Times Cited: 3
Targeting cancer stem cells in multiple myeloma
Emine Gulsen Gunes, Metin Gunes, Jianhua Yu, et al.
Trends in cancer (2024) Vol. 10, Iss. 8, pp. 733-748
Open Access | Times Cited: 3
Development of a Novel Peptide-Based PET Tracer [68Ga]Ga-DOTA-BP1 for BCMA Detection in Multiple Myeloma
Lele Song, Sujun Jiang, Qi Yang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 17, pp. 15118-15130
Closed Access | Times Cited: 3
Nelfinavir inhibits human DDI2 and potentiates cytotoxicity of proteasome inhibitors
Yuan Gu, Xin Wang, Yu Wang, et al.
Cellular Signalling (2020) Vol. 75, pp. 109775-109775
Closed Access | Times Cited: 24
Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates
Aiko Nagayama, Neelima Vidula, Aditya Bardia
ONCOLOGY (2021), Iss. 3505, pp. 249-254
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top